Close Menu

genomic datasets

AMP AD 2.0 will look to bring precision medicine technologies to Alzheimer's biomarker and target discovery over the next five year.

German bioinformatics startup 4HF Biotec targets early-stage biotech development with technology to predict drug sensitivity based on tumor genetic profiles.

The partners will offer an end-to-end microbiome sequencing and analysis service through Transnetyx's global network of model organism research customers.

Multinational nephrology firm Fresenius Medical Care eventually wants as many as 200,000 samples in its registry and aims to sequence 20,000 patients this year.

The partners will use Adaptive's ImmunoSeq T-Map technology to analyze immune response to cancer antigens across AstraZeneca's oncology portfolio.

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

NHGRI has moved the Genotype-Tissue Expression dataset entirely to the cloud in an effort to democratize access to the huge but formerly pricey compendium.

Q2 Solutions will run Adaptive's NGS-based immune cell receptor profiling assay for its pharma and biotech clients, potentially in COVID-19 vaccine trials.

The firm said it will use the financing for ongoing development of software and learning models.

Genosity will combine its Integrated Genomic Toolkit with Israel-based Igentify's genetic counseling software, which both firms will comarket.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.